Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oprozomib - Onyx Pharmaceuticals

Drug Profile

Oprozomib - Onyx Pharmaceuticals

Alternative Names: ONO-7058; ONX-012; ONX-0912; PR-047

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onyx Pharmaceuticals
  • Class Amides; Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules; Thiazoles
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase I/II Haematological malignancies; Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 23 Sep 2019 Amgen completes a phase Ib/II trial for Multiple Myeloma in USA (NCT01881789)
  • 12 Aug 2019 Onyx Pharmaceuticals completes a phase Ib/II trial in Haematological malignancies (Monotherapy, Second-line therapy or greater) in USA (NCT01416428)
  • 10 Jul 2019 Onyx Therapeutics completes a phase I pharmacokinetics trial for Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02244112)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top